Status:
COMPLETED
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Lead Sponsor:
Swedish Medical Center
Collaborating Sponsors:
Pfizer
Conditions:
Lung Cancer
Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less th...
Detailed Description
To participate in this study, patients must have disease that can be measured on a CT scan. Brain metastases are OK if stable. Pregnant and/or nursing women may not participate. This drug has been app...
Eligibility Criteria
Inclusion
- Bronchoalveolar carcinoma with disease measurable on CAT scan
- Any lung adenocarcinoma in a never-smoker (less than 100 cigarettes lifetime) with disease measurable on CAT scan
- Stage IIIB or IV
Exclusion
- Uncontrolled hypertension
- Unstable brain metastases
- Pregnant/nursing women
- Uncontrolled thyroid disease
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00430261
Start Date
January 1 2007
End Date
October 1 2010
Last Update
October 6 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Swedish Cancer Institute
Seattle, Washington, United States, 98104